6 completed, 1 terminated, 1 withdrawn. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow linifanib: new trials by email Literature Review of linifanib trials Research Report on linifanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis Linifanib, BIBW2992, Axitinib - Endometriosis, Endometriosis Ovary | Phase 1 / Phase 2 | Withdrawn | BioGene Pharmaceutical Ltd. | 2021-10-10 | 2021-10-29 | |
| Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer linifanib - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2011-06-01 | 2014-08-26 |
| Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer ABT-869, bevacizumab, oxaliplatin - Advanced Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 159 | 2008-10-01 | 2013-05-15 |
| Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer ABT-869, paclitaxel, Placebo for ABT-869 - Metastatic Breast Cancer | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 10 | 2008-07-01 | 2013-01-29 |
| Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) ABT-869, Placebo for ABT-869, Carboplatin - Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 145 | 2008-06-01 | 2013-04-29 |
| Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) ABT-869 - Advanced Hepatocellular Carcinoma | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 44 | 2007-09-01 | 2013-01-04 |
| Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) ABT-869 .25 mg/kg, ABT-869 0.10 mg/kg - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 140 | 2007-08-01 | 2013-04-05 |
| Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib ABT-869 - Advanced Renal Cell Carcinoma | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 53 | 2007-06-01 | 2013-01-04 |
Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Rectal Neoplasms (2) · Breast Neoplasms (1) · Endometriosis (1) · Neoplasm Metastasis (1)
AbbVie (prior sponsor, Abbott) (6) · BioGene Pharmaceutical Ltd. (1) · Vanderbilt-Ingram Cancer Center (1)
United States (7) · Canada (4) · Singapore (3) · Australia (2) · Brazil (2) · Czechia (2) · Russia (2) · Taiwan (2) · Belgium (1) · France (1) · Greece (1) · Mexico (1) · New Zealand (1) · Poland (1) · Portugal (1)
Justin L. Ricker, MD (3) · Justin Ricker, MD (2) · Jordan Berlin, MD (1) · Mark D. McKee, MD (1)